Last reviewed · How we verify
Atazanavir, Norvir and Truvada — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Atazanavir, Norvir and Truvada (Atazanavir, Norvir and Truvada) — The University of Texas Health Science Center, Houston.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Atazanavir, Norvir and Truvada TARGET | Atazanavir, Norvir and Truvada | The University of Texas Health Science Center, Houston | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Atazanavir, Norvir and Truvada CI watch — RSS
- Atazanavir, Norvir and Truvada CI watch — Atom
- Atazanavir, Norvir and Truvada CI watch — JSON
- Atazanavir, Norvir and Truvada alone — RSS
Cite this brief
Drug Landscape (2026). Atazanavir, Norvir and Truvada — Competitive Intelligence Brief. https://druglandscape.com/ci/atazanavir-norvir-and-truvada. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab